table of content
1 Study Coverage
1.1 Chronic Idiopathic Constipation Drugs Product Introduction
1.2 Global Chronic Idiopathic Constipation Drugs Outlook 2017 VS 2022 VS 2028
1.2.1 Global Chronic Idiopathic Constipation Drugs Sales in US$ Million for the Year 2017-2028
1.2.2 Global Chronic Idiopathic Constipation Drugs Sales in Volume for the Year 2017-2028
1.3 United States Chronic Idiopathic Constipation Drugs Outlook 2017 VS 2022 VS 2028
1.3.1 United States Chronic Idiopathic Constipation Drugs Sales in US$ Million for the Year 2017-2028
1.3.2 United States Chronic Idiopathic Constipation Drugs Sales in Volume for the Year 2017-2028
1.4 Chronic Idiopathic Constipation Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4.1 The Market Share of United States Chronic Idiopathic Constipation Drugs in Global, 2017 VS 2022 VS 2028
1.4.2 The Growth Rate of Chronic Idiopathic Constipation Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.5 Chronic Idiopathic Constipation Drugs Market Dynamics
1.5.1 Chronic Idiopathic Constipation Drugs Industry Trends
1.5.2 Chronic Idiopathic Constipation Drugs Market Drivers
1.5.3 Chronic Idiopathic Constipation Drugs Market Challenges
1.5.4 Chronic Idiopathic Constipation Drugs Market Restraints
1.6 Study Objectives
1.7 Years Considered
2 Market by Type
2.1 Chronic Idiopathic Constipation Drugs Market Segment by Type
2.1.1 Linaclotide
2.1.2 Lubiprostone
2.1.3 Others
2.2 Global Chronic Idiopathic Constipation Drugs Market Size by Type
2.2.1 Global Chronic Idiopathic Constipation Drugs Sales in Value, by Type (2017, 2022 & 2028)
2.2.2 Global Chronic Idiopathic Constipation Drugs Sales in Volume, by Type (2017, 2022 & 2028)
2.2.3 Global Chronic Idiopathic Constipation Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028)
2.3 United States Chronic Idiopathic Constipation Drugs Market Size by Type
2.3.1 United States Chronic Idiopathic Constipation Drugs Sales in Value, by Type (2017, 2022 & 2028)
2.3.2 United States Chronic Idiopathic Constipation Drugs Sales in Volume, by Type (2017, 2022 & 2028)
2.3.3 United States Chronic Idiopathic Constipation Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028)
3 Market by Application
3.1 Chronic Idiopathic Constipation Drugs Market Segment by Application
3.1.1 Hospital Pharmacies
3.1.2 Retail Pharmacies
3.1.3 Online Pharmacies
3.2 Global Chronic Idiopathic Constipation Drugs Market Size by Application
3.2.1 Global Chronic Idiopathic Constipation Drugs Sales in Value, by Application (2017, 2022 & 2028)
3.2.2 Global Chronic Idiopathic Constipation Drugs Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 Global Chronic Idiopathic Constipation Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028)
3.3 United States Chronic Idiopathic Constipation Drugs Market Size by Application
3.3.1 United States Chronic Idiopathic Constipation Drugs Sales in Value, by Application (2017, 2022 & 2028)
3.3.2 United States Chronic Idiopathic Constipation Drugs Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 United States Chronic Idiopathic Constipation Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028)
4 Global Chronic Idiopathic Constipation Drugs Competitor Landscape by Company
4.1 Global Chronic Idiopathic Constipation Drugs Market Size by Company
4.1.1 Top Global Chronic Idiopathic Constipation Drugs Manufacturers Ranked by Revenue (2021)
4.1.2 Global Chronic Idiopathic Constipation Drugs Revenue by Manufacturer (2017-2022)
4.1.3 Global Chronic Idiopathic Constipation Drugs Sales by Manufacturer (2017-2022)
4.1.4 Global Chronic Idiopathic Constipation Drugs Price by Manufacturer (2017-2022)
4.2 Global Chronic Idiopathic Constipation Drugs Concentration Ratio (CR)
4.2.1 Chronic Idiopathic Constipation Drugs Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Chronic Idiopathic Constipation Drugs in 2021
4.2.3 Global Chronic Idiopathic Constipation Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Chronic Idiopathic Constipation Drugs Manufacturing Base Distribution, Product Type
4.3.1 Global Chronic Idiopathic Constipation Drugs Manufacturers, Headquarters and Distribution of Producing Region
4.3.2 Manufacturers Chronic Idiopathic Constipation Drugs Product Type
4.3.3 Date of International Manufacturers Enter into Chronic Idiopathic Constipation Drugs Market
4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
4.5 United States Chronic Idiopathic Constipation Drugs Market Size by Company
4.5.1 Top Chronic Idiopathic Constipation Drugs Players in United States, Ranked by Revenue (2021)
4.5.2 United States Chronic Idiopathic Constipation Drugs Revenue by Players (2020, 2021 & 2022)
4.5.3 United States Chronic Idiopathic Constipation Drugs Sales by Players (2020, 2021 & 2022)
5 Global Chronic Idiopathic Constipation Drugs Market Size by Region
5.1 Global Chronic Idiopathic Constipation Drugs Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Chronic Idiopathic Constipation Drugs Market Size in Volume by Region (2017-2028)
5.2.1 Global Chronic Idiopathic Constipation Drugs Sales in Volume by Region: 2017-2022
5.2.2 Global Chronic Idiopathic Constipation Drugs Sales in Volume Forecast by Region (2023-2028)
5.3 Global Chronic Idiopathic Constipation Drugs Market Size in Value by Region (2017-2028)
5.3.1 Global Chronic Idiopathic Constipation Drugs Sales in Value by Region: 2017-2022
5.3.2 Global Chronic Idiopathic Constipation Drugs Sales in Value by Region: 2023-2028
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Chronic Idiopathic Constipation Drugs Market Size YoY Growth 2017-2028
6.1.2 North America Chronic Idiopathic Constipation Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Chronic Idiopathic Constipation Drugs Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Chronic Idiopathic Constipation Drugs Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Chronic Idiopathic Constipation Drugs Market Size YoY Growth 2017-2028
6.3.2 Europe Chronic Idiopathic Constipation Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Chronic Idiopathic Constipation Drugs Market Size YoY Growth 2017-2028
6.4.2 Latin America Chronic Idiopathic Constipation Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Chronic Idiopathic Constipation Drugs Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Chronic Idiopathic Constipation Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Pfizer
7.1.1 Pfizer Corporation Information
7.1.2 Pfizer Description and Business Overview
7.1.3 Pfizer Chronic Idiopathic Constipation Drugs Sales, Revenue and Gross Margin (2017-2022)
7.1.4 Pfizer Chronic Idiopathic Constipation Drugs Products Offered
7.1.5 Pfizer Recent Development
7.2 Glaxosmithkline
7.2.1 Glaxosmithkline Corporation Information
7.2.2 Glaxosmithkline Description and Business Overview
7.2.3 Glaxosmithkline Chronic Idiopathic Constipation Drugs Sales, Revenue and Gross Margin (2017-2022)
7.2.4 Glaxosmithkline Chronic Idiopathic Constipation Drugs Products Offered
7.2.5 Glaxosmithkline Recent Development
7.3 Roche Holding AG
7.3.1 Roche Holding AG Corporation Information
7.3.2 Roche Holding AG Description and Business Overview
7.3.3 Roche Holding AG Chronic Idiopathic Constipation Drugs Sales, Revenue and Gross Margin (2017-2022)
7.3.4 Roche Holding AG Chronic Idiopathic Constipation Drugs Products Offered
7.3.5 Roche Holding AG Recent Development
7.4 Sanofi
7.4.1 Sanofi Corporation Information
7.4.2 Sanofi Description and Business Overview
7.4.3 Sanofi Chronic Idiopathic Constipation Drugs Sales, Revenue and Gross Margin (2017-2022)
7.4.4 Sanofi Chronic Idiopathic Constipation Drugs Products Offered
7.4.5 Sanofi Recent Development
7.5 Bayer AG
7.5.1 Bayer AG Corporation Information
7.5.2 Bayer AG Description and Business Overview
7.5.3 Bayer AG Chronic Idiopathic Constipation Drugs Sales, Revenue and Gross Margin (2017-2022)
7.5.4 Bayer AG Chronic Idiopathic Constipation Drugs Products Offered
7.5.5 Bayer AG Recent Development
7.6 Merck
7.6.1 Merck Corporation Information
7.6.2 Merck Description and Business Overview
7.6.3 Merck Chronic Idiopathic Constipation Drugs Sales, Revenue and Gross Margin (2017-2022)
7.6.4 Merck Chronic Idiopathic Constipation Drugs Products Offered
7.6.5 Merck Recent Development
7.7 Eli Lilly
7.7.1 Eli Lilly Corporation Information
7.7.2 Eli Lilly Description and Business Overview
7.7.3 Eli Lilly Chronic Idiopathic Constipation Drugs Sales, Revenue and Gross Margin (2017-2022)
7.7.4 Eli Lilly Chronic Idiopathic Constipation Drugs Products Offered
7.7.5 Eli Lilly Recent Development
7.8 Allergens
7.8.1 Allergens Corporation Information
7.8.2 Allergens Description and Business Overview
7.8.3 Allergens Chronic Idiopathic Constipation Drugs Sales, Revenue and Gross Margin (2017-2022)
7.8.4 Allergens Chronic Idiopathic Constipation Drugs Products Offered
7.8.5 Allergens Recent Development
7.9 Chugai Pharmaceutical
7.9.1 Chugai Pharmaceutical Corporation Information
7.9.2 Chugai Pharmaceutical Description and Business Overview
7.9.3 Chugai Pharmaceutical Chronic Idiopathic Constipation Drugs Sales, Revenue and Gross Margin (2017-2022)
7.9.4 Chugai Pharmaceutical Chronic Idiopathic Constipation Drugs Products Offered
7.9.5 Chugai Pharmaceutical Recent Development
7.10 Ferring International Center S.A
7.10.1 Ferring International Center S.A Corporation Information
7.10.2 Ferring International Center S.A Description and Business Overview
7.10.3 Ferring International Center S.A Chronic Idiopathic Constipation Drugs Sales, Revenue and Gross Margin (2017-2022)
7.10.4 Ferring International Center S.A Chronic Idiopathic Constipation Drugs Products Offered
7.10.5 Ferring International Center S.A Recent Development
7.11 Synergy Pharmaceuticals
7.11.1 Synergy Pharmaceuticals Corporation Information
7.11.2 Synergy Pharmaceuticals Description and Business Overview
7.11.3 Synergy Pharmaceuticals Chronic Idiopathic Constipation Drugs Sales, Revenue and Gross Margin (2017-2022)
7.11.4 Synergy Pharmaceuticals Chronic Idiopathic Constipation Drugs Products Offered
7.11.5 Synergy Pharmaceuticals Recent Development
7.12 Salix Pharmaceuticals Ltd
7.12.1 Salix Pharmaceuticals Ltd Corporation Information
7.12.2 Salix Pharmaceuticals Ltd Description and Business Overview
7.12.3 Salix Pharmaceuticals Ltd Chronic Idiopathic Constipation Drugs Sales, Revenue and Gross Margin (2017-2022)
7.12.4 Salix Pharmaceuticals Ltd Products Offered
7.12.5 Salix Pharmaceuticals Ltd Recent Development
7.13 Sucampo Pharmaceuticals Inc
7.13.1 Sucampo Pharmaceuticals Inc Corporation Information
7.13.2 Sucampo Pharmaceuticals Inc Description and Business Overview
7.13.3 Sucampo Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Sales, Revenue and Gross Margin (2017-2022)
7.13.4 Sucampo Pharmaceuticals Inc Products Offered
7.13.5 Sucampo Pharmaceuticals Inc Recent Development
7.14 Ironwood Pharmaceuticals Inc
7.14.1 Ironwood Pharmaceuticals Inc Corporation Information
7.14.2 Ironwood Pharmaceuticals Inc Description and Business Overview
7.14.3 Ironwood Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Sales, Revenue and Gross Margin (2017-2022)
7.14.4 Ironwood Pharmaceuticals Inc Products Offered
7.14.5 Ironwood Pharmaceuticals Inc Recent Development
7.15 Bausch Health
7.15.1 Bausch Health Corporation Information
7.15.2 Bausch Health Description and Business Overview
7.15.3 Bausch Health Chronic Idiopathic Constipation Drugs Sales, Revenue and Gross Margin (2017-2022)
7.15.4 Bausch Health Products Offered
7.15.5 Bausch Health Recent Development
7.16 Daiichi Sankyo
7.16.1 Daiichi Sankyo Corporation Information
7.16.2 Daiichi Sankyo Description and Business Overview
7.16.3 Daiichi Sankyo Chronic Idiopathic Constipation Drugs Sales, Revenue and Gross Margin (2017-2022)
7.16.4 Daiichi Sankyo Products Offered
7.16.5 Daiichi Sankyo Recent Development
7.17 Cosmo Pharmaceuticals SA
7.17.1 Cosmo Pharmaceuticals SA Corporation Information
7.17.2 Cosmo Pharmaceuticals SA Description and Business Overview
7.17.3 Cosmo Pharmaceuticals SA Chronic Idiopathic Constipation Drugs Sales, Revenue and Gross Margin (2017-2022)
7.17.4 Cosmo Pharmaceuticals SA Products Offered
7.17.5 Cosmo Pharmaceuticals SA Recent Development
7.18 Progenics Pharmaceuticals Inc
7.18.1 Progenics Pharmaceuticals Inc Corporation Information
7.18.2 Progenics Pharmaceuticals Inc Description and Business Overview
7.18.3 Progenics Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Sales, Revenue and Gross Margin (2017-2022)
7.18.4 Progenics Pharmaceuticals Inc Products Offered
7.18.5 Progenics Pharmaceuticals Inc Recent Development
7.19 Theravance Biopharma Inc
7.19.1 Theravance Biopharma Inc Corporation Information
7.19.2 Theravance Biopharma Inc Description and Business Overview
7.19.3 Theravance Biopharma Inc Chronic Idiopathic Constipation Drugs Sales, Revenue and Gross Margin (2017-2022)
7.19.4 Theravance Biopharma Inc Products Offered
7.19.5 Theravance Biopharma Inc Recent Development
8 Industry Chain and Sales Channels Analysis
8.1 Chronic Idiopathic Constipation Drugs Industry Chain Analysis
8.2 Chronic Idiopathic Constipation Drugs Key Raw Materials
8.2.1 Key Raw Materials
8.2.2 Chronic Idiopathic Constipation Drugs Distributors
8.3 Chronic Idiopathic Constipation Drugs Production Mode & Process
8.4 Chronic Idiopathic Constipation Drugs Sales and Marketing
8.4.1 Chronic Idiopathic Constipation Drugs Sales Channels
8.4.2 Chronic Idiopathic Constipation Drugs Distributors
8.5 Chronic Idiopathic Constipation Drugs Customers
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
